慢性淋巴细胞白血病中低频del17p亚克隆的临床意义:ALLG/CLLARC CLL5试验数据
该研究基于ALLG/CLLARC CLL5试验,在95例慢性淋巴细胞白血病患者中检出15例低频del17p克隆(<25%)。不伴TP53突变的低频del17p患者无进展生存和总生存均显著长于高频del17p克隆患者。11/15例低频del17p患者中还观察到单独del17p或del13q亚克隆,提示低频del17p未必预后不良,并挑战del13q为CLL起始事件的观点。
要点
- 低频del17p(<25%)见于15/95例CLL患者。
- 不伴TP53突变的低频del17p患者PFS和OS显著优于高频del17p患者。
- 低频del17p不一定提示不良预后,del13q可能并非起始事件。
核心结论
- 低频del17p不一定导致CLL不良预后,并挑战del13q作为CLL起始事件的观念。
研究设计与样本
- 基于ALLG/CLLARC CLL5试验,纳入95例CLL患者检测低频del17p克隆(<25%)。
主要发现
- 15/95例患者检出低频del17p克隆(<25%)。
- 不伴TP53突变的低频del17p患者PFS和OS显著长于高频del17p克隆患者。
- 11/15例低频del17p患者中观察到单独del17p或del13q亚克隆。
临床怎么用
- 解读CLL患者低频del17p(<25%)时需结合TP53突变状态,不应直接等同于高危。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical significance of low-frequency deletions of 17p13 [tumour protein p53 (TP53)] in patients with chronic lymphocytic leukaemia (CLL) is currently unclear. Low-frequency del17p clones (<25%) were identified in 15/95 patients in the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial. Patients with low del17p, without tumour protein p53 (TP53) mutation, had significantly longer progression-free survival and overall survival durations than patients with high del17p clones. In 11/15 cases with low-frequency del17p, subclones solely with del17p or del13q were also noted. These data suggest that low-frequency del17p does not necessarily confer a poor outcome in CLL and challenges the notion of del13q as a founding event in CLL.
引用
- Do C, Best OG, Thurgood L, et al. Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial. Br J Haematol. 2021. PMID: 33851417. doi:10.1111/bjh.17394
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。